Global Oral GLP-1 Agonist Market Growth 2024-2030

Global Oral GLP-1 Agonist Market Growth 2024-2030

GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.

The global Oral GLP-1 Agonist market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Oral GLP-1 Agonist Industry Forecast” looks at past sales and reviews total world Oral GLP-1 Agonist sales in 2023, providing a comprehensive analysis by region and market sector of projected Oral GLP-1 Agonist sales for 2024 through 2030. With Oral GLP-1 Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral GLP-1 Agonist industry.

This Insight Report provides a comprehensive analysis of the global Oral GLP-1 Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral GLP-1 Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral GLP-1 Agonist market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral GLP-1 Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral GLP-1 Agonist.

United States market for Oral GLP-1 Agonist is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Oral GLP-1 Agonist is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Oral GLP-1 Agonist is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Oral GLP-1 Agonist players cover Novo Nordisk, Eli Lilly, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Oral GLP-1 Agonist market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Semaglutide
Non-peptide

Segmentation by Application:
Diabetes
Obesity

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Eli Lilly

Key Questions Addressed in this Report

What is the 10-year outlook for the global Oral GLP-1 Agonist market?

What factors are driving Oral GLP-1 Agonist market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Oral GLP-1 Agonist market opportunities vary by end market size?

How does Oral GLP-1 Agonist break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.